靖因药业估值18亿冲刺港股IPO：上半年扭亏为盈，腾讯参股

Core Viewpoint - Sirius Therapeutics-B (靖因药业) has submitted its listing application to the Hong Kong Stock Exchange, focusing on the clinical and commercial potential of siRNA therapies, with three main product pipelines targeting coagulation disorders, cardiovascular metabolic diseases, and obesity [3]. Group 1: Company Overview - Sirius Therapeutics-B is a global clinical-stage biotechnology company dedicated to maximizing the clinical and commercial value of siRNA therapies [3]. - The company has developed three major product pipelines, with SRSD107 as its core product, targeting coagulation factor XI and currently undergoing Phase II clinical trials in Europe [3]. - The company has established a global collaboration with CRISPR Therapeutics for the development and commercialization of SRSD107 [3]. Group 2: Financial Performance - The company reported no revenue or sales costs during the historical performance period [4]. - For 2023 and 2024, other income and gains were RMB 8.81 million and RMB 9.79 million, respectively, while the net loss attributable to shareholders was RMB -309.09 million and RMB -342.00 million [4][6]. - In the first half of 2025, other income and gains surged to RMB 144.61 million, a year-on-year increase of 3094.81%, with a net profit of RMB 34.46 million, marking a turnaround from losses [4][6]. Group 3: Funding and Valuation - Since its inception, the company has completed three rounds of financing, raising a total of approximately USD 144 million, with the latest round valuing the company at USD 25.3 million (approximately RMB 1.8 billion) [7]. - Major shareholders include OrbiMed Entities and Creacion Ventures, each holding approximately 20.23% of the company's issued share capital [10].